MP28-14 REAL-WORLD SURVIVAL OUTCOMES ASSOCIATED WITH IMMUNOTHERAPY, TARGETED THERAPY, AND COMBINATION THERAPY FOR METASTATIC PAPILLARY RENAL CELL CARCINOMA

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP28-14 REAL-WORLD SURVIVAL OUTCOMES ASSOCIATED WITH IMMUNOTHERAPY, TARGETED THERAPY, AND COMBINATION THERAPY FOR METASTATIC PAPILLARY RENAL CELL CARCINOMA Carlos Riveros, Sanjana Ranganathan, Jiaqiong Xu, Emily Huang, Courtney Chang, Michael Geng, Dharam Kaushik, Monica morgan, brian j., Miles taliah muhammad, maryam anis, monty aghazadeh, jun zhang, eleni efstathiou, Zachary Klaassen, Michael A. Brooks, Rini Brian, Christopher J.D. Wallis, and Raj Satkunasivam Carlos RiverosCarlos Riveros More articles by this author , Sanjana RanganathanSanjana Ranganathan More articles by this author , Jiaqiong XuJiaqiong Xu More articles by this author , Emily HuangEmily Huang More articles by this author , Courtney ChangCourtney Chang More articles by this author , Michael GengMichael Geng More articles by this author , Dharam KaushikDharam Kaushik More articles by this author , Monica morganMonica morgan More articles by this author , brian j.brian j. More articles by this author , taliah muhammadtaliah muhammad More articles by this author , maryam anismaryam anis More articles by this author , monty aghazadehmonty aghazadeh More articles by this author , jun zhangjun zhang More articles by this author , eleni efstathioueleni efstathiou More articles by this author , Zachary KlaassenZachary Klaassen More articles by this author , Michael A. BrooksMichael A. Brooks More articles by this author , Rini BrianRini Brian More articles by this author , Christopher J.D. WallisChristopher J.D. Wallis More articles by this author , and Raj SatkunasivamRaj Satkunasivam More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003256.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Much of the data used to advise patients with metastatic papillary renal cell carcinoma (pRCC) is derived from studies in the setting of metastatic clear cell renal cell carcinoma (ccRCC). The current standard of care for patients with metastatic ccRCC is immunotherapy (IO) with or without targeted therapy (TT). Except for a few phase II randomized clinical trials, the benefit of IO or IO+TT combination has not been thoroughly explored in metastatic pRCC. We sought to describe real-world utilization trends of TT, IO, and IO+TT and their impact on overall survival (OS) in the setting of metastatic pRCC with or without cytoreductive nephrectomy (CN). METHODS: We queried the National Cancer Database (NCDB) to identify adult patients with de novo metastatic pRCC who had received first-line TT, IO, or IO+TT. The primary outcomes of interest were trends in systemic therapy utilization and OS benefit. We performed multivariable Cox proportional hazards regression analysis to evaluate the association between the type of systemic therapy and OS, after adjusting for receipt of CN and other covariates. RESULTS: A total of 737 patients with metastatic pRCC were identified: 512 (69.5%), 126 (17.1%), and 99 (13.4%) had received TT, IO, and IO+TT, respectively. The proportion of patients who received IO and IO+TT increased steadily during the study period. After adjusting for baseline differences, CN was associated with a benefit in OS (HR 0.63, 95% CI 0.48-0.84). However, neither IO (HR 1.10; 95% CI 0.81-1.49) nor IO+TT (HR 0.83, 95% CI 0.57-1.19) were associated with better OS compared to TT alone. CONCLUSIONS: In patients with metastatic pRCC, neither IO or IO+TT were associated with an improvement in OS, compared to TT alone. Source of Funding: N/A © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e376 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Carlos Riveros More articles by this author Sanjana Ranganathan More articles by this author Jiaqiong Xu More articles by this author Emily Huang More articles by this author Courtney Chang More articles by this author Michael Geng More articles by this author Dharam Kaushik More articles by this author Monica morgan More articles by this author brian j. More articles by this author taliah muhammad More articles by this author maryam anis More articles by this author monty aghazadeh More articles by this author jun zhang More articles by this author eleni efstathiou More articles by this author Zachary Klaassen More articles by this author Michael A. Brooks More articles by this author Rini Brian More articles by this author Christopher J.D. Wallis More articles by this author Raj Satkunasivam More articles by this author Expand All Advertisement PDF downloadLoading ...